By Gwendolyn Wu
Published Sept. 8, 2026
In a significant strategic pivot, San Francisco-based biotech startup Moonwalk Biosciences has secured $70 million in Series B financing to accelerate the development of a new class of obesity treatments. The company, which initially gained industry attention for its ambitious plans to mine the epigenome for therapeutic targets, is shifting its primary focus toward RNA interference (RNAi) technology licensed from the Chinese firm Suzhou Siran Biotechnology.
With this fresh capital infusion, Moonwalk aims to initiate human clinical trials for its lead candidate, MW101, by the end of 2027. This development marks a transition from a pure-play epigenetics firm to a diversified biotechnology player seeking to disrupt the current obesity market, which is currently dominated by the GLP-1 receptor agonist class.
Main Facts: A Strategic Evolution
When Moonwalk Biosciences emerged from stealth in 2024, it did so with high-profile backing from venture capital giants like Arch Venture Partners and Khosla Ventures. At the time, the company’s mandate was clear: utilize gene-editing technology licensed from the Broad Institute to "rewrite" the epigenome—the chemical markers that dictate how genes are expressed—to treat disease.
Two years later, the company’s mission has evolved. CEO Alex Aravanis describes the current trajectory not as a abandonment of its origins, but as a pragmatic "evolution of the story." By leveraging RNAi—a technology that silences genes before they can produce disease-causing proteins—Moonwalk believes it has found a faster, more scalable path to the clinic.
The $70 million Series B round was co-led by Alpha Wave Global and YK Bioventures, with participation from a notable syndicate including Eli Lilly, Gaorong Ventures, and early investors Arch and Khosla.
Chronology of a Biotech Pivot
The evolution of Moonwalk Biosciences reflects the rapid pace of the biotechnology sector, where agility often determines long-term viability.
- Early 2024: Moonwalk Biosciences launches with significant venture backing, aiming to revolutionize medicine through epigenetic editing licensed from the Broad Institute.
- Early 2026: Recognizing the clinical potential of RNA interference, Moonwalk secures a licensing agreement with Suzhou Siran Biotechnology Co. to acquire specialized RNAi technology.
- Mid-2026: Scientific teams at Moonwalk confirm that targeting adipose (body fat) tissue via RNAi offers a viable and efficient pathway for therapeutic intervention.
- September 8, 2026: Moonwalk announces a $70 million Series B funding round, officially pivoting its primary research focus toward siRNA (small interfering RNA) treatments for cardiometabolic diseases.
- Late 2027 (Target): The company expects to file for and initiate first-in-human clinical trials for its lead candidate, MW101.
Supporting Data: The Science of Metabolic Modulation
The core of Moonwalk’s new strategy lies in its mechanism of action. Unlike the current market-leading GLP-1 drugs (such as semaglutide and tirzepatide), which primarily function as appetite suppressants, Moonwalk’s approach targets the fat cells themselves.
Targeting Adipose Tissue
Moonwalk’s siRNA technology is designed to modulate energy regulation and lipolysis—the metabolic breakdown of fat. By silencing specific genes within adipose tissue, the company hopes to increase the body’s natural metabolic rate.
CEO Alex Aravanis notes that this approach may offer two distinct clinical advantages:
- Gastrointestinal Tolerability: By bypassing the gut-brain axis used by GLP-1s, the company anticipates fewer of the nausea and digestive issues that plague many users of current weight-loss medications.
- Muscle Preservation: A persistent critique of current GLP-1 weight-loss regimens is the significant loss of muscle mass alongside fat. Moonwalk’s mechanism, which focuses on metabolic efficiency, is theoretically positioned to spare muscle tissue while targeting fat storage.
The Competitive Landscape
Moonwalk is entering a crowded field. The race to develop "second-generation" obesity drugs is intensifying, with several notable players:
- ADARx Pharmaceuticals: A direct competitor that recently filed for an IPO, focusing on nucleic acid therapies for metabolic disorders.
- Wave Life Sciences: Currently in mid-stage human testing with its drug WVE-007. While Wave has demonstrated "substantial reductions of fat," its recent clinical data failed to meet the high expectations of some investors, highlighting the volatility and difficulty of this drug class.
- The Liver vs. Fat Divide: A key differentiator for Moonwalk is its focus on adipose cells. While companies like Wave often target liver-based pathways, Moonwalk’s focus on the primary site of fat storage may provide a unique clinical profile.
Official Responses and Perspectives
In an interview following the funding announcement, CEO Alex Aravanis defended the company’s move away from its original pure-epigenetics focus. "Our scientists looked at the epigenome to find new targets," Aravanis stated. "But we determined that RNAi treatments would be a faster way for us to bring those insights to the clinic."
Investors appear to share his optimism. By bringing in strategic partners like Eli Lilly—a titan in the obesity space—Moonwalk has secured not just capital, but institutional validation. The backing of Lilly is particularly telling, as the pharmaceutical giant continues to aggressively expand its footprint in the obesity and cardiometabolic market.
Implications: A New Era for Obesity Medicine
The implications of Moonwalk’s shift are two-fold for the broader healthcare market.
1. The Diversification of Weight-Loss Therapeutics
The obesity market is currently a "winner-take-all" landscape dominated by injectable GLP-1 agonists. However, the medical community has begun to express concerns regarding long-term maintenance and the quality of weight loss. If Moonwalk can prove that metabolic modulation via siRNA is safe and effective in humans, it could provide a "maintenance" drug that works in tandem with—or as an alternative to—GLP-1s.
2. The Rise of "RNAi-as-a-Service"
Moonwalk’s reliance on licensed technology from Suzhou Siran Biotechnology highlights a growing trend of cross-border biotechnology collaboration. Western startups are increasingly looking toward the innovation hubs in China to bolster their pipelines with mature or highly specialized delivery technologies, such as siRNA, which have seen rapid advancements in Asia.
3. Investor Expectations
The lukewarm reception to Wave Life Sciences’ recent data serves as a cautionary tale for Moonwalk. Investors are no longer easily impressed by "reductions in fat." They are looking for clear evidence of superior efficacy, a favorable safety profile, and, most importantly, patient adherence. For Moonwalk, the period between now and the end of 2027 will be critical. The company must bridge the gap between bench-side promise and clinical reality.
As Moonwalk prepares for the transition into a clinical-stage company, the industry will be watching closely. Whether this "evolution of the story" results in a breakthrough treatment or another addition to the growing list of metabolic drug candidates remains to be seen. However, with $70 million in the bank and a clear focus on the limitations of current therapies, Moonwalk Biosciences is positioning itself as a formidable, if unconventional, contender in the global fight against obesity.
About the Author
